The probability of revision sinus surgery including removing nasal polyps is higher if the patient has asthma or is on ...

GSK (GSK) stock in focus as its experimental drug depemokimab undergoes EU review for asthma and nasal polyps. Read more here ...

AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...

In CRS with and without nasal polyps, medical treatment, including nasal and oral corticosteroids, is the first therapeutic option. The treatment of CRS still remains an unmet need ...

THURSDAY, Feb. 6, 2025 (HealthDay News) -- A few baseline characteristics can predict the need for recurrent endoscopic sinus ...

Nasal microbiota transplantation could revolutionise the treatment of chronic rhinosinusitis and respiratory tract infections ...

They typically result from seasonal allergies or a bacterial infection requiring medical treatment ... an underlying medical condition, such as nasal polyps. Also, it’s best to talk with ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 09:00 Hrs [IST] GSK plc announced ...

Exposure to irritants has been shown to increase nasal symptoms and cause exacerbations ... Although the studies of the different treatments have a high level of evidence (Ib) and grade of ...

Chronic rhinosinusitis with nasal polyps is treated with nasally administered corticosteroids and, as the diseases progresses, also with orally administered corticosteroids. If these treatments ...